For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

The biggest names in biotech descend on San Francisco for #JPM19. Is it worth it for some of the smallest names in the industry?

For four days in January, the biggest names in biotech descend on the J.P. Morgan Healthcare Conference in San Francisco to unveil splashy merger and acquisition announcements, offer out-of-the-box meditations on drug pricing, and schmooze.

But some of the smallest and newest names in biotech are there, too, trying not to get lost in the noise.

These companies aren’t making headline-grabbing presentations or hosting big parties. But the conference gives tiny startups and even small- and mid-size public companies a pivotal — and unmissable — opportunity, executives at three different companies told STAT. For them, the conference is their chance to

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readSociety
U.S. To Begin Health Screenings At Three Airports For Cases Of Novel Chinese Virus
U.S. authorities on Friday are set to begin screening travelers arriving in the country from Wuhan, China, amid an ongoing outbreak of a novel viral infection there that has already led to cases among travelers in two other countries. Passengers arri
STAT4 min readSociety
‘How Long Do I Have?’ A Website On Cancer Survival Rates, From The Co-founder Of GoodRx, Seeks To Provide Clarity
A new online tool from the co-founder of GoodRx seeks to answer a simple but daunting question for cancer patients: "How long do I have?"
STAT1 min readSociety
Listen: A J.P. Morgan Recap, A Plan To Bust Pharma Monopolies, And A Website For Cancer Patients
Why weren't there any big deals announced this week? What does the word "equivalar" mean? And why is information about prognosis so hard to find? Find out on the latest…